Kalaris Therapeutics (KLRS) Total Current Liabilities (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Total Current Liabilities of $8.1 million for Q1 2026, up 13.12% year-over-year from $7.1 million in Q1 2025, and down 16.83% quarter-over-quarter from $9.7 million in Q4 2025.
Kalaris Therapeutics (KLRS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 13.12% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (up 13.12% YoY), while the FY2025 annual figure was $9.7 million, down 60.68% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $8.1 million, down from $9.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $33.1 million in Q3 2023, with the low at $1.4 million in Q3 2024.
- The 5-year median for Total Current Liabilities is $18.6 million (2022), against an average of $16.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 95.73% in 2024, then surged 329.53% in 2025.
- Kalaris Therapeutics' Total Current Liabilities stood at $24.3 million in 2022, then grew by 16.55% to $28.4 million in 2023, then retreated by 12.92% to $24.7 million in 2024, then sank by 60.68% to $9.7 million in 2025, then slipped by 16.83% to $8.1 million in 2026.
- Business Quant data shows KLRS's Total Current Liabilities at $8.1 million in Q1 2026, $9.7 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Kalaris Therapeutics | 99.00 Mn | 99.00 Mn | - | 8.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.74 Mn |
| Mar 31, 2026 | 8.08 Mn |
| Dec 31, 2025 | 9.71 Mn |
| Sep 30, 2025 | 6.07 Mn |
| Jun 30, 2025 | 7.65 Mn |
| Mar 31, 2025 | 7.14 Mn |
| Dec 31, 2024 | 24.70 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 7.66 Mn |
| Dec 31, 2023 | 28.37 Mn |
| Sep 30, 2023 | 33.07 Mn |
| Jun 30, 2023 | 30.56 Mn |
| Mar 31, 2023 | 24.96 Mn |
| Dec 31, 2022 | 24.34 Mn |
| Sep 30, 2022 | 20.72 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 18.64 Mn |
| Dec 31, 2021 | 37.85 Mn |
| Sep 30, 2021 | 24.17 Mn |